Bictegravir, emtricitabine, and tenofovir alafenamide versus ritonavir-boosted protease inhibitor-based antiretroviral therapy in people with HIV and viral suppression on second-line therapy in Haiti: an open-label, randomised, non-inferiority trial.

Saved in:
Bibliographic Details
Title: Bictegravir, emtricitabine, and tenofovir alafenamide versus ritonavir-boosted protease inhibitor-based antiretroviral therapy in people with HIV and viral suppression on second-line therapy in Haiti: an open-label, randomised, non-inferiority trial.
Authors: Severe P; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti., Pierre S; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti., Homeus F; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti., Marc JB; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti., Trevisi L; Harvard Medical School, Boston, MA, USA., Aristhomene ML; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti., Bernadin GR; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti., Lavoile K; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti., Rivera V; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti., Duchatellier CF; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti., Joseph MJ; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti., Wu J; Analysis Group Inc, Boston, MA, USA., Rouzier V; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti; Weill Cornell Medical College, New York, NY, USA., Preval F; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti., Jean E; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti., Bernadin J; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti., Zion A; Analysis Group Inc, Boston, MA, USA., Pierre Louis Forestal G; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti., Avila-Rios S; Center for Research in Infectious Diseases, National Institute of Respiratory Diseases, Mexico City, Mexico., Garcia Morales C; Center for Research in Infectious Diseases, National Institute of Respiratory Diseases, Mexico City, Mexico., Zhang A; Analysis Group Inc, Boston, MA, USA., Israelski D; Gilead Sciences, Foster City, CA, USA., Apollon A; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti., Dumont E; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti., Fox E; Cornell University, Ithaca, NY, USA., Cremieux PY; Analysis Group Inc, Boston, MA, USA., Pape JW; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti; Weill Cornell Medical College, New York, NY, USA., Collins SE; Gilead Sciences, Foster City, CA, USA., Liautaud B; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti., Sax PE; Harvard Medical School, Boston, MA, USA; Brigham and Women's Hospital, Boston, MA, USA., Koenig SP; Harvard Medical School, Boston, MA, USA; Brigham and Women's Hospital, Boston, MA, USA. Electronic address: skoenig@bwh.harvard.edu.
Source: The lancet. HIV [Lancet HIV] 2025 Sep; Vol. 12 (9), pp. e616-e626.
Publication Type: Journal Article; Randomized Controlled Trial; Equivalence Trial
Journal Info: Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101645355 Publication Model: Print Cited Medium: Internet ISSN: 2352-3018 (Electronic) Linking ISSN: 23523018 NLM ISO Abbreviation: Lancet HIV Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2352-3018
DOI:10.1016/S2352-3018(25)00130-4